相关实验视频

Updated: Jul 7, 2025

Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma

Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma

Published on: April 15, 2022

在多发性骨髓瘤的治疗决策定制中,t的作用 (§11;14)

Martina Kleber^1,2, Ioannis Ntanasis-Stathopoulos³, Evangelos Terpos³

¹Department of Internal Medicine, Clinic Hirslanden Zurich, 8032 Zurich, Switzerland.

|December 23, 2023

概括

多发性骨髓瘤 (MM) 的t(11;14) 遗传异常表明BCL2依赖. 像venetoclax这样的BCL2抑制剂在这个MM亚组中显示出有效性,指导个性化治疗.

科学领域:

血液学血液学血液学
在瘤学瘤学.
遗传学是一个遗传学.

背景情况:

多发性骨髓瘤 (MM) 是血细胞的癌症,其特征是遗传异常.
11;14) 转位是MM中常见的一次性异常,定义了一个独特的患者亚组.
这个小组表现出独特的临床特征和对BCL2的生存依赖.

研究的目的:

在MM中审查t(11;14) 的生物学.
总结t(11;14) 在风险分层和向治疗选择中的作用.
评估BCL2抑制剂在t(11;14) 阳性MM中有效性和安全性.

主要方法:

文献综述侧重于MM的遗传异常.
对具有t(11;14) 转位的患者的临床数据的分析.
在MM治疗中对BCL2抑制剂 (例如,venetoclax) 的研究的评估.

主要成果:

t(11;14) 与BCL2过度表达和依赖有关.
威尼托克拉克斯在复发性/耐药性MM (RRMM) 中表现出显著的疗效,t{11;14).
) 状态影响治疗决策和治疗策略.

结论:

t(11;14) 是MM风险分层和治疗选择的关键生物标志物.
抑制BCL2是一种有前途的向疗法,用于t(11;14) 阳性MM.
对于这个MM亚组,精准医学方法正在进步.

关键词:

14) 一十四) 的.在多发性骨髓瘤的预后.转移 (11个地方)治疗策略治疗策略

更多相关视频

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...